“It’s exciting to apply our experience in collecting reliable, real-time PRO data to help INSYS determine the effectiveness of Fentanyl SL Spray,” said Doug Engfer, president and CEO of invivodata. “We are pleased to have contributed to their research efforts and look forward to forming a long-term relationship with the company as it continues to address the significant unmet medical needs of patients with breakthrough cancer pain.”
About invivodata inc.
invivodata combines behavioral science, information technology, and clinical research expertise to capture high quality clinical trial data directly from patients. invivodata’s electronic Patient Reported Outcomes (ePRO) solutions, which are based on over 20 years of research, deliver reliable patient self-reported data by driving patient compliance with the protocol and eliminating recall biases that plague paper-based self-report data. invivodata’s solutions include comprehensive trial-support services that facilitate the collection of ePRO data, web-based access to study data and operational reports that give researchers and sponsors visibility into study progress, and scientific and regulatory consulting on the use of PRO data in a regulated
environment. invivodata’s solution has been used in more than 275 clinical programs and is the industry-leading ePRO system in delivering primary efficacy data for FDA drug approvals. invivodata inc. is a privately held company with global headquarters in Pittsburgh, Pa., USA; its European headquarters is in London, England; and its technology devel
Copyright©2010 Vocus, Inc.
All rights reserved